Business News

    Neuren Pharmaceuticals' (ASX:NEU) NNZ-2591 trial shows improvements in Phelan-McDermid Syndrome

    Article Image

    Neuren Pharmaceuticals flagged results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome, a severe neurological disorder.

    Both clinicians and caregivers observed improvements across multiple measures, including communication, behaviour, cognition/learning, and socialisation.

    Based on Clinical Global Impression of Improvement and Caregiver Overall Impression of Change assessments, improvements were noted in 16 out of 18 and 15 out of 18 children, respectively.

    NNZ-2591 was also safe and well-tolerated, with no clinically significant changes in laboratory values or other safety parameters.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa